Intensive Sequential Chemotherapy for Untreated Poor-Risk Non-Hodgkin’s Lymphoma

1998 ◽  
pp. 21-31
Author(s):  
A. M. Stoppa ◽  
R. Bouabdallah ◽  
N. Vey ◽  
J. F. Rossi ◽  
R. Costello ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Sequential Chemotherapy ◽  
Poor Risk ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Autologous Stem-Cell Transplantation for Poor-Risk and Relapsed Intermediate- and High-Grade Non-Hodgkin's Lymphoma

2000 ◽  
Vol 1 (1) ◽  
pp. 46-54 ◽  
Author(s):  
Auayporn Nademanee ◽  
Arturo Molina ◽  
Andrew Dagis ◽  
David S. Snyder ◽  
Margaret R. O'Donnell ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
High Grade ◽  
Poor Risk ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

1994 ◽  
Vol 12 (12) ◽  
pp. 2543-2551 ◽  
Author(s):  
C Haioun ◽  
E Lepage ◽  
C Gisselbrecht ◽  
B Coiffier ◽  
A Bosly ◽  
...  
Keyword(s):  
Complete Remission ◽  
Confidence Interval ◽  
Hodgkin’S Lymphoma ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Hodgkin's Lymphoma ◽  
Induction Treatment ◽  
Sequential Chemotherapy ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

PURPOSE Intensive chemotherapy followed by autotransplantation has given promising results in partially responding or sensitive relapsed patients with aggressive non-Hodgkin's lymphoma. In 1987, we designed a randomized study to evaluate the potential benefit of a high-dose regimen containing cyclophosphamide, carmustine, and etoposide (CBV) followed by autotransplantation over a consolidative sequential chemotherapy (ifosfamide, etoposide, asparaginase, and cytarabine) in patients in first complete remission with intermediate- and high-grade non-Hodgkin's lymphoma. PATIENTS AND METHODS Patients were younger than 55 years and had at least one adverse prognostic factor. Induction treatment was that of the LNH84 protocol with an open randomization on the anthracycline. Patients in complete remission were further randomly assigned to receive either consolidation procedure. RESULTS After induction treatment, 464 patients were assessable for the consolidation phase. With a median follow-up duration of 28 months, the 3-year disease-free survival rate was 52% (95% confidence interval, 45% to 59%) in the sequential chemotherapy arm and 59% (95% confidence interval, 52% to 66%) in the autologous transplant arm (P = .46, relative risk = 0.90). The 3-year survival rate did not differ between sequential chemotherapy and autotransplantation, at 71% (95% confidence interval, 64% to 78%) and 69% (95% confidence interval, 62% to 76%), respectively (P = .60, relative risk = 1.11). CONCLUSION For such a subset of patients, consolidation with the CBV regimen followed by autologous bone marrow transplantation is not superior to sequential chemotherapy.

Chemotherapy of advanced non-Hodgkin's lymphoma

1979 ◽  
Vol 8 (3) ◽  
pp. 667-684 ◽  
Author(s):  
Arthur T. Skarin ◽  
George P. Canellos
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document